Issue 32, 2015

A core/shell/satellite anticancer platform for 808 NIR light-driven multimodal imaging and combined chemo-/photothermal therapy

Abstract

In this contribution, a novel multifunctional anti-cancer nanoplatform has been firstly constructed by conjugating a photothermal agent (CuS nanoparticles) and a cancer cell target agent (folic acid, FA) onto the surface of mesoporous silica coated core–shell–shell up-conversion nanoparticles (UCNPs). It was found that the doxorubicin (DOX) loaded system exhibits obvious pH and NIR-responsive release behaviour and the drug can be targetedly delivered to the cancer cells by a receptor mediated endocytosis manner. Furthermore, both photothermal therapy (PTT) and chemotherapy can be triggered simultaneously by a single 808 nm near infrared (NIR) light source, thus leading to a synergistic effect. The combined chemo- and NIR photothermal therapy can significantly improve the therapeutic efficacy compared to any single therapy, which has been evidenced by both in vitro and in vivo results. Besides, due to the doped rare earth ions, the platform also exhibits good up-conversion luminescence (UCL), computed tomography (CT) and magnetic resonance imaging (MRI) properties. Based on the excellent multimodal imaging and anti-tumor properties, the multifunctional nanoplatform should be a promising candidate for imaging-guided anti-cancer therapy.

Graphical abstract: A core/shell/satellite anticancer platform for 808 NIR light-driven multimodal imaging and combined chemo-/photothermal therapy

Supplementary files

Article information

Article type
Paper
Submitted
11 May 2015
Accepted
07 Jul 2015
First published
10 Jul 2015

Nanoscale, 2015,7, 13747-13758

Author version available

A core/shell/satellite anticancer platform for 808 NIR light-driven multimodal imaging and combined chemo-/photothermal therapy

G. Yang, R. Lv, F. He, F. Qu, S. Gai, S. Du, Z. Wei and P. Yang, Nanoscale, 2015, 7, 13747 DOI: 10.1039/C5NR03085D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements